TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
P/B ratio for TransMedics Group, Inc. (TMDX)
P/B ratio as of 2023: 18.71
According to TransMedics Group, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 18.71. At the end of 2022 the company had a P/B ratio of 9.74.
P/B ratio history for TransMedics Group, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 18.71 |
| 2022 | 9.74 |
| 2021 | 7.80 |
| 2020 | 4.73 |
| 2019 | 4.83 |
| 2018 | -89.19 |
| 2017 | -1.92 |
| 2016 | 8.35 |